{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Breast cancer", "Wnt", "apoptosis", "epithelial-mesenchymal transition (EMT)", "sinensetin"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38410229", "DateRevised": {"Year": "2024", "Month": "02", "Day": "29"}, "Article": {"Language": ["eng"], "ELocationID": ["10.21037/tcr-23-1317"], "ArticleDate": [{"Year": "2024", "Month": "01", "Day": "12"}], "Journal": {"ISSN": "2219-6803", "JournalIssue": {"Volume": "13", "Issue": "1", "PubDate": {"Year": "2024", "Month": "Jan", "Day": "31"}}, "Title": "Translational cancer research", "ISOAbbreviation": "Transl Cancer Res"}, "ArticleTitle": "Sinensetin suppresses breast cancer cell progression via Wnt/\u03b2-catenin pathway inhibition.", "Pagination": {"StartPage": "348", "EndPage": "362", "MedlinePgn": "348-362"}, "Abstract": {"AbstractText": ["Although there are many treatments for breast cancer, such as surgery, radiotherapy, chemotherapy, estrogen receptor antagonists, immune checkpoint inhibitors and so on. However, safer and more effective therapeutic drugs for breast cancer are needed. Sinensetin, a safer therapeutic drugs, come from citrus species and medicinal plants used in traditional medicine, while its role and underlying mechanism in breast cancer remain unclear. Our study aimed to investigate the role and mechanism of sinensetin in breast cancer.", "Cell Counting Kit-8 (CCK-8) was used to determine the safe concentration of sinensetin in MCF-10A, MCF7 and MDA-MB-231 cells; 120 \u03bcM sinensetin was used in subsequent experiments. Real time polymerase chain reaction (RT-PCR), Western blotting, Terminal Deoxynucleotidyl Transferase mediated dUTP Nick-End Labeling (TUNEL) apoptosis assay, Transwell invasion assay and Clone formation assay were used in this study to determine cell viability, mRNA expression, protein levels, apoptosis, proliferation, invasion and so on.", "Herein, our results showed that 120 \u03bcM sinensetin suppressed the cell viability and promoted apoptosis of MCF7 and MDA-MB-231 cells. Treatment with 120 \u00b5M sinensetin for 24 h showed no significant toxicity to normal mammary cells; 120 \u03bcM sinensetin decreased cell proliferation, invasion, and epithelial-mesenchymal transition (EMT), and downregulated \u03b2-catenin, lymphatic enhancing factor 1 (LEF1), T-cell factor (TCF) 1/TCF7, and TCF3/TCF7L1 expression in MCF7 and MDA-MB-231 cells. The Wnt agonist SKL2001 reversed the inhibitory effect of sinensetin on cell survival, metastasis, and EMT. Sinensetin-induced downregulation of \u03b2-catenin, LEF1, and TCF1/TCF7 expression were upregulated by SKL2001 in MCF7 and MDA-MB-231 cells.", "In summary, sinensetin suppressed the metastasis of breast cancer cell via inhibition of Wnt/\u03b2-catenin pathway and there were no adverse effects on normal breast cells. Our study confirmed the role of sinensetin in breast cancer cells and provided a better understanding of the underlying mechanism."], "CopyrightInformation": "2024 Translational Cancer Research. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China."}], "LastName": "Zhu", "ForeName": "Shengqian", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China."}], "LastName": "Meng", "ForeName": "Lifei", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China."}], "LastName": "Wei", "ForeName": "Peng", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Hepatobiliary Surgery, Ningbo First Hospital, Ningbo, China."}], "LastName": "Gu", "ForeName": "Guowen", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Plastic and Reconstructive Surgery, The Third Hospital of Ninghai County, Ningbo, China."}], "LastName": "Duan", "ForeName": "Keli", "Initials": "K"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Transl Cancer Res", "NlmUniqueID": "101585958", "ISSNLinking": "2218-676X"}, "CoiStatement": "Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1317/coif). The authors have no conflicts of interest to declare."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Lin J, Yin X, Zeng Y, et al. Progress and prospect: Biosynthesis of plant natural products based on plant chassis. Biotechnol Adv 2023;69:108266. 10.1016/j.biotechadv.2023.108266", "ArticleIdList": ["10.1016/j.biotechadv.2023.108266", "37778531"]}, {"Citation": "Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod 2020;83:770-803. 10.1021/acs.jnatprod.9b01285", "ArticleIdList": ["10.1021/acs.jnatprod.9b01285", "32162523"]}, {"Citation": "Montan\u00e9 X, Kowalczyk O, Reig-Vano B, et al. Current Perspectives of the Applications of Polyphenols and Flavonoids in Cancer Therapy. Molecules 2020;25:3342. 10.3390/molecules25153342", "ArticleIdList": ["10.3390/molecules25153342", "PMC7435624", "32717865"]}, {"Citation": "de Luna FCF, Ferreira WAS, Casseb SMM, et al. Anticancer Potential of Flavonoids: An Overview with an Emphasis on Tangeretin. Pharmaceuticals (Basel) 2023;16:1229. 10.3390/ph16091229", "ArticleIdList": ["10.3390/ph16091229", "PMC10537037", "37765037"]}, {"Citation": "Torello CO, Alvarez MC, Olalla Saad ST. Polyphenolic Flavonoid Compound Quercetin Effects in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Molecules 2021;26:5781. 10.3390/molecules26195781", "ArticleIdList": ["10.3390/molecules26195781", "PMC8510366", "34641325"]}, {"Citation": "Cotoraci C, Ciceu A, Sasu A, et al. The Anti-Leukemic Activity of Natural Compounds. Molecules 2021;26:2709. 10.3390/molecules26092709", "ArticleIdList": ["10.3390/molecules26092709", "PMC8124534", "34063044"]}, {"Citation": "Xu Y, Lv X, Yang G, et al. Simultaneous separation of six pure polymethoxyflavones from sweet orange peel extract by high performance counter current chromatography. Food Chem 2019;292:160-5. 10.1016/j.foodchem.2019.04.031", "ArticleIdList": ["10.1016/j.foodchem.2019.04.031", "31054661"]}, {"Citation": "Kubatka P, Koklesova L, Mazurakova A, et al. Cell plasticity modulation by flavonoids in resistant breast carcinoma targeting the nuclear factor kappa B signaling. Cancer Metastasis Rev 2023. [Epub ahead of print]. Doi: .10.1007/s10555-023-10134-x", "ArticleIdList": ["10.1007/s10555-023-10134-x", "37789138"]}, {"Citation": "Melfi F, Carradori S, Mencarelli N, et al. Natural products as a source of new anticancer chemotypes. Expert Opin Ther Pat 2023. [Epub ahead of print]. Doi: .10.1080/13543776.2023.2265561", "ArticleIdList": ["10.1080/13543776.2023.2265561", "37775999"]}, {"Citation": "Borah N, Gunawardana S, Torres H, et al. 5,6,7,3\u2019,4\u2019,5\u2019-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle. Int J Oncol 2017;51:1685-93. 10.3892/ijo.2017.4157", "ArticleIdList": ["10.3892/ijo.2017.4157", "PMC5673012", "29039514"]}, {"Citation": "Kim E, Kim YJ, Ji Z, et al. ROR activation by Nobiletin enhances antitumor efficacy via suppression of I\u03baB/NF-\u03baB signaling in triple-negative breast cancer. Cell Death Dis 2022;13:374. 10.1038/s41419-022-04826-5", "ArticleIdList": ["10.1038/s41419-022-04826-5", "PMC9018867", "35440077"]}, {"Citation": "Fan S, Xu H, Liu H, et al. Inhibition of cancer cell growth by Tangeretin flavone in drug-resistant MDA-MB-231 human breast carcinoma cells is facilitated via targeting cell apoptosis, cell cycle phase distribution, cell invasion and activation of numerous Caspases. J BUON 2019;24:1532-7.", "ArticleIdList": ["31646804"]}, {"Citation": "Sun Y, Duan X, Wang F, et al. Inhibitory effects of flavonoids on glucose transporter 1 (GLUT1): From library screening to biological evaluation to structure-activity relationship. Toxicology 2023;488:153475. 10.1016/j.tox.2023.153475", "ArticleIdList": ["10.1016/j.tox.2023.153475", "36870413"]}, {"Citation": "Li X, Li Y, Wang Y, et al. Sinensetin suppresses angiogenesis in liver cancer by targeting the VEGF/VEGFR2/AKT signaling pathway. Exp Ther Med 2022;23:360. 10.3892/etm.2022.11287", "ArticleIdList": ["10.3892/etm.2022.11287", "PMC9019764", "35493423"]}, {"Citation": "Kim SM, Rampogu S, Vetrivel P, et al. Transcriptome analysis of sinensetin-treated liver cancer cells guided by biological network analysis. Oncol Lett 2021;21:355. 10.3892/ol.2021.12616", "ArticleIdList": ["10.3892/ol.2021.12616", "PMC7968004", "33747212"]}, {"Citation": "Huang B, Zhai M, Qin A, et al. Sinensetin flavone exhibits potent anticancer activity against drug-resistant human gallbladder adenocarcinoma cells by targeting PTEN/PI3K/AKT signalling pathway, induces cellular apoptosis and inhibits cell migration and invasion. J BUON 2020;25:1251-6.", "ArticleIdList": ["32521933"]}, {"Citation": "Pereira CV, Duarte M, Silva P, et al. Polymethoxylated Flavones Target Cancer Stemness and Improve the Antiproliferative Effect of 5-Fluorouracil in a 3D Cell Model of Colorectal Cancer. Nutrients 2019;11:326. 10.3390/nu11020326", "ArticleIdList": ["10.3390/nu11020326", "PMC6412836", "30717428"]}, {"Citation": "Chen P, Chen F, Guo Z, et al. Recent advancement in bioeffect, metabolism, stability, and delivery systems of apigenin, a natural flavonoid compound: challenges and perspectives. Front Nutr 2023;10:1221227. 10.3389/fnut.2023.1221227", "ArticleIdList": ["10.3389/fnut.2023.1221227", "PMC10410563", "37565039"]}, {"Citation": "Lawton TJ. Update on the Use of Molecular Subtyping in Breast Cancer. Adv Anat Pathol 2023;30:368-73. 10.1097/PAP.0000000000000416", "ArticleIdList": ["10.1097/PAP.0000000000000416", "37746905"]}, {"Citation": "Gomes I, Abreu C, Costa L, et al. The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer. Cancers (Basel) 2023;15:4835. 10.3390/cancers15194835", "ArticleIdList": ["10.3390/cancers15194835", "PMC10571967", "37835528"]}, {"Citation": "Shivnani P, Shekhawat S, Prajapati A. Cancer Cachexia and breast cancer stem cell signalling \u2013 A crosstalk of signalling molecules. Cell Signal 2023;110:110847. 10.1016/j.cellsig.2023.110847", "ArticleIdList": ["10.1016/j.cellsig.2023.110847", "37557973"]}, {"Citation": "Doloi R, Gupta SM. MicroRNAs: The key players regulating the crosstalk between Hippo and Wnt/\u03b2-catenin pathways in breast cancer. Life Sci 2023;329:121980. 10.1016/j.lfs.2023.121980", "ArticleIdList": ["10.1016/j.lfs.2023.121980", "37516428"]}, {"Citation": "Yokoyama N, Nakayama H, Iwabuchi K. Novel Insights into the Role of Kras in Myeloid Differentiation: Engaging with Wnt/\u03b2-Catenin Signaling. Cells 2023;12:322. 10.3390/cells12020322", "ArticleIdList": ["10.3390/cells12020322", "PMC9857056", "36672256"]}, {"Citation": "Koelman EMR, Yeste-V\u00e1zquez A, Grossmann TN. Targeting the interaction of \u03b2-catenin and TCF/LEF transcription factors to inhibit oncogenic Wnt signaling. Bioorg Med Chem 2022;70:116920. 10.1016/j.bmc.2022.116920", "ArticleIdList": ["10.1016/j.bmc.2022.116920", "35841828"]}, {"Citation": "Moon SJ, Choi HJ, Kye YH, et al. CTTN Overexpression Confers Cancer Stem Cell-like Properties and Trastuzumab Resistance via DKK-1/WNT Signaling in HER2 Positive Breast Cancer. Cancers (Basel) 2023;15:1168. 10.3390/cancers15041168", "ArticleIdList": ["10.3390/cancers15041168", "PMC9954024", "36831511"]}, {"Citation": "Mandal S, Gamit N, Varier L, et al. Inhibition of breast cancer stem-like cells by a triterpenoid, ursolic acid, via activation of Wnt antagonist, sFRP4 and suppression of miRNA-499a-5p. Life Sci 2021;265:118854. 10.1016/j.lfs.2020.118854", "ArticleIdList": ["10.1016/j.lfs.2020.118854", "33278391"]}, {"Citation": "Kasprzak A. Angiogenesis-Related Functions of Wnt Signaling in Colorectal Carcinogenesis. Cancers (Basel) 2020;12:3601. 10.3390/cancers12123601", "ArticleIdList": ["10.3390/cancers12123601", "PMC7761462", "33276489"]}, {"Citation": "Gao Y, Chen N, Fu Z, et al. Progress of Wnt Signaling Pathway in Osteoporosis. Biomolecules 2023;13:483. 10.3390/biom13030483", "ArticleIdList": ["10.3390/biom13030483", "PMC10046187", "36979418"]}, {"Citation": "Hsueh YC, Hodgkinson CP, Gomez JA. The role of Sfrp and DKK proteins in cardiomyocyte development. Physiol Rep 2021;9:e14678. 10.14814/phy2.14678", "ArticleIdList": ["10.14814/phy2.14678", "PMC7883806", "33587322"]}, {"Citation": "Wu XL, Lin SG, Mao YW, et al. Wnt/\u03b2-catenin signalling pathway in breast cancer cells and its effect on reversing tumour drug resistance by alkaloids extracted from traditional Chinese medicine. Expert Rev Mol Med 2023;25:e21. 10.1017/erm.2023.16", "ArticleIdList": ["10.1017/erm.2023.16", "37332167"]}, {"Citation": "Castagnoli L, Tagliabue E, Pupa SM. Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness. Int J Mol Sci 2020;21:9069. 10.3390/ijms21239069", "ArticleIdList": ["10.3390/ijms21239069", "PMC7730964", "33260642"]}, {"Citation": "Xu WN, Zheng HL, Yang RZ, et al. Mitochondrial NDUFA4L2 attenuates the apoptosis of nucleus pulposus cells induced by oxidative stress via the inhibition of mitophagy. Exp Mol Med 2019;51:1-16. 10.1038/s12276-019-0331-2", "ArticleIdList": ["10.1038/s12276-019-0331-2", "PMC6861227", "31740659"]}, {"Citation": "Liao S, Chen H, Liu M, et al. Aquaporin 9 inhibits growth and metastasis of hepatocellular carcinoma cells via Wnt/\u03b2-catenin pathway. Aging (Albany NY) 2020;12:1527-44. 10.18632/aging.102698", "ArticleIdList": ["10.18632/aging.102698", "PMC7053619", "31969493"]}, {"Citation": "Lazarian G, Friedrich C, Quinquenel A, et al. Stabilization of \u03b2-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma. Oncogene 2020;39:2934-47. 10.1038/s41388-020-1183-x", "ArticleIdList": ["10.1038/s41388-020-1183-x", "32034308"]}, {"Citation": "Zhang X, Yu X. Crosstalk between Wnt/\u03b2-catenin signaling pathway and DNA damage response in cancer: a new direction for overcoming therapy resistance. Front Pharmacol 2023;14:1230822. 10.3389/fphar.2023.1230822", "ArticleIdList": ["10.3389/fphar.2023.1230822", "PMC10433774", "37601042"]}, {"Citation": "Shen X, Gao C, Li H, et al. Natural compounds: Wnt pathway inhibitors with therapeutic potential in lung cancer. Front Pharmacol 2023;14:1250893. 10.3389/fphar.2023.1250893", "ArticleIdList": ["10.3389/fphar.2023.1250893", "PMC10568034", "37841927"]}, {"Citation": "Pandey P, Khan F, Seifeldin SA, et al. Targeting Wnt/\u03b2-Catenin Pathway by Flavonoids: Implication for Cancer Therapeutics. Nutrients 2023;15:2088. 10.3390/nu15092088", "ArticleIdList": ["10.3390/nu15092088", "PMC10181252", "37432240"]}, {"Citation": "Mukherjee N, Panda CK. Wnt/\u03b2-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons. Clin Breast Cancer 2020;20:361-70. 10.1016/j.clbc.2020.04.004", "ArticleIdList": ["10.1016/j.clbc.2020.04.004", "32416986"]}, {"Citation": "Mu\u00f1oz JP, P\u00e9rez-Moreno P, P\u00e9rez Y, et al. The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application. Diagnostics (Basel) 2023;13:3072. 10.3390/diagnostics13193072", "ArticleIdList": ["10.3390/diagnostics13193072", "PMC10572677", "37835815"]}, {"Citation": "Miziak P, Baran M, B\u0142aszczak E, et al. Estrogen Receptor Signaling in Breast Cancer. Cancers (Basel) 2023;15:4689. 10.3390/cancers15194689", "ArticleIdList": ["10.3390/cancers15194689", "PMC10572081", "37835383"]}, {"Citation": "Androutsopoulos VP, Ruparelia K, Arroo RR, et al. CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology 2009;264:162-70. 10.1016/j.tox.2009.07.023", "ArticleIdList": ["10.1016/j.tox.2009.07.023", "19666078"]}, {"Citation": "Manthey JA, Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem 2002;50:5837-43. 10.1021/jf020121d", "ArticleIdList": ["10.1021/jf020121d", "12358447"]}, {"Citation": "Kim SM, Ha SE, Lee HJ, et al. Sinensetin Induces Autophagic Cell Death through p53-Related AMPK/mTOR Signaling in Hepatocellular Carcinoma HepG2 Cells. Nutrients 2020;12:2462. 10.3390/nu12082462", "ArticleIdList": ["10.3390/nu12082462", "PMC7468969", "32824273"]}, {"Citation": "Mitra S, Dash R. Natural Products for the Management and Prevention of Breast Cancer. Evid Based Complement Alternat Med 2018;2018:8324696. 10.1155/2018/8324696", "ArticleIdList": ["10.1155/2018/8324696", "PMC5846366", "29681985"]}, {"Citation": "Riby JE, Firestone GL, Bjeldanes LF. 3,3\u2019-diindolylmethane reduces levels of HIF-1alpha and HIF-1 activity in hypoxic cultured human cancer cells. Biochem Pharmacol 2008;75:1858-67. 10.1016/j.bcp.2008.01.017", "ArticleIdList": ["10.1016/j.bcp.2008.01.017", "PMC2387239", "18329003"]}, {"Citation": "Rahman KW, Li Y, Wang Z, et al. Gene expression profiling revealed survivin as a target of 3,3\u2019-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006;66:4952-60. 10.1158/0008-5472.CAN-05-3918", "ArticleIdList": ["10.1158/0008-5472.CAN-05-3918", "16651453"]}, {"Citation": "B\u00f6mer M, P\u00e9rez-Salam\u00f3 I, Florance HV, et al. Jasmonates induce Arabidopsis bioactivities selectively inhibiting the growth of breast cancer cells through CDC6 and mTOR. New Phytol 2021;229:2120-34. 10.1111/nph.17031", "ArticleIdList": ["10.1111/nph.17031", "PMC8022592", "33124043"]}, {"Citation": "Sun Z, Zhou C, Liu F, et al. Inhibition of breast cancer cell survival by Xanthohumol via modulation of the Notch signaling pathway in vivo and in vitro. Oncol Lett 2018;15:908-16.", "ArticleIdList": ["PMC5772922", "29422966"]}, {"Citation": "Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, et al. WNT Signaling in Tumors: The Way to Evade Drugs and Immunity. Front Immunol 2019;10:2854. 10.3389/fimmu.2019.02854", "ArticleIdList": ["10.3389/fimmu.2019.02854", "PMC6934036", "31921125"]}, {"Citation": "Yamaguchi K, Nagatoishi S, Tsumoto K, et al. Discovery of chemical probes that suppress Wnt/\u03b2-catenin signaling through high-throughput screening. Cancer Sci 2020;111:783-94. 10.1111/cas.14297", "ArticleIdList": ["10.1111/cas.14297", "PMC7060471", "31912579"]}, {"Citation": "Liu D, Chen L, Zhao H, et al. Small molecules from natural products targeting the Wnt/\u03b2-catenin pathway as a therapeutic strategy. Biomed Pharmacother 2019;117:108990. 10.1016/j.biopha.2019.108990", "ArticleIdList": ["10.1016/j.biopha.2019.108990", "31226638"]}, {"Citation": "Bhuvanalakshmi G, Basappa, Rangappa KS, et al. Breast Cancer Stem-Like Cells Are Inhibited by Diosgenin, a Steroidal Saponin, by the Attenuation of the Wnt \u03b2-Catenin Signaling via the Wnt Antagonist Secreted Frizzled Related Protein-4. Front Pharmacol 2017;8:124. 10.3389/fphar.2017.00124", "ArticleIdList": ["10.3389/fphar.2017.00124", "PMC5357646", "28373842"]}, {"Citation": "Abdel-Razeq H. Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives. Front Oncol 2023;13:1265197. 10.3389/fonc.2023.1265197", "ArticleIdList": ["10.3389/fonc.2023.1265197", "PMC10539549", "37781190"]}, {"Citation": "Kaidar-Person O, Offersen BV, Tramm T, et al. The King is in the altogether: Radiation therapy after oncoplastic breast surgery. Breast 2023;72:103584. 10.1016/j.breast.2023.103584", "ArticleIdList": ["10.1016/j.breast.2023.103584", "PMC10562190", "37783134"]}, {"Citation": "Tarekegn K, Keskinkilic M, Kristoff TJ, et al. The role of immune checkpoint inhibition in triple negative breast cancer. Expert Rev Anticancer Ther 2023;23:1095-106. 10.1080/14737140.2023.2265059", "ArticleIdList": ["10.1080/14737140.2023.2265059", "37771270"]}, {"Citation": "Ferro A, Generali D, Caffo O, et al. Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? Semin Oncol 2023;50:90-101. 10.1053/j.seminoncol.2023.08.002", "ArticleIdList": ["10.1053/j.seminoncol.2023.08.002", "37673696"]}, {"Citation": "Anbar HS, Isa Z, Elounais JJ, et al. Steroid sulfatase inhibitors: the current landscape. Expert Opin Ther Pat 2021;31:453-72. 10.1080/13543776.2021.1910237", "ArticleIdList": ["10.1080/13543776.2021.1910237", "33783295"]}, {"Citation": "Mohamed A, Kruse M, Tran J. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer. Expert Rev Anticancer Ther 2023;23:1071-84. 10.1080/14737140.2023.2262764", "ArticleIdList": ["10.1080/14737140.2023.2262764", "37747062"]}, {"Citation": "Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77. 10.1021/np068054v", "ArticleIdList": ["10.1021/np068054v", "17309302"]}]}], "History": [{"Year": "2023", "Month": "7", "Day": "26"}, {"Year": "2023", "Month": "11", "Day": "17"}, {"Year": "2024", "Month": "2", "Day": "27", "Hour": "6", "Minute": "46"}, {"Year": "2024", "Month": "2", "Day": "27", "Hour": "6", "Minute": "45"}, {"Year": "2024", "Month": "2", "Day": "27", "Hour": "3", "Minute": "36"}, {"Year": "2024", "Month": "1", "Day": "31"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38410229", "PMC10894327", "10.21037/tcr-23-1317", "tcr-13-01-348"]}}]}